南财智讯1月29日电，智翔金泰发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-48063.73万元至-58744.56万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-52363.18万元至-63044.01万元。报告期内，公司营业收入较上年同期实现大幅增长，主要原因系公 司首款商业化产品赛立奇单抗注射液(金立希®)销售收入稳步增长，以及确认GR1803注射液授权许可及 商业化协议的合同履约义务所对应的授权许可收入；报告期内，公司坚持源头创新，高效推进各在研项 目进度。随着多款产品进入临床研究阶段及核心产品进入关键临床试验阶段，公司对在研项目保持较高 水平的研发投入。同时，公司2022年针对核心团队实施的股权激励计划服务期已于2024年届满，2025年 度无股份支付费用，因此报告期内的相应费用减少。在上述因素的综合作用下，公司预计2025年度归属 于母公司所有者的净利润及归属于母公司所有者的扣除非经常性损益的净利润均为亏损，但亏损幅度较 上年同期显著收窄。 ...

智翔金泰公告称，预计2025年年度营收20,944.98万元到25,087.94万元，同比增长595.96%到733.62%； 研发费用42,521.28万元到51,970.45万元，同比减少14.77%到30.27%；归母净利润-48,063.73万元 到-58,744.56万元，亏损同比减少26.32%到39.71%；扣非归母净利润-52,363.18万元到-63,044.01万元， 亏损同比减少21.62%到34.90%。营收增长系首款产品销售收入增长及授权许可收入确认，亏损收窄因 无股份支付费用。数据未经审计。 ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Core Viewpoint - The company is focusing on the autoimmune disease sector, with multiple products at various stages of development and commercialization [1] Group 1: Product Approvals and Development - The company's product, Sairiqi monoclonal injection, has received approval for two indications and is included in the national medical insurance directory [1] - The NDA for Tailiqi monoclonal injection has been accepted for one indication, while four other indications are in Phase III clinical trials [1] - The company has several other autoimmune products at different stages of research and development [1] Group 2: Commercialization Strategy - The current commercialization strategy emphasizes the autoimmune field, particularly focusing on Sairiqi for psoriasis and Tailiqi for atopic dermatitis and urticaria, which are expected to create synergistic effects in the next one to two years [1] - The applications for rabies and tetanus products are in different medical departments, and the selection of partners considers various factors such as usage scenarios, distribution channels, promotional capabilities, and contract pricing [1]

格隆汇1月26日丨智翔金泰(688443.SH)近日在线上会议交流时表示，GR1802注射液(泰利奇拜单抗)的 中、重度特应性皮炎适应症已经于2025年9月新药上市申请获受理，目前在上市申请审评阶段；慢性鼻 窦炎伴鼻息肉、慢性自发性荨麻疹、成人和青少年季节性过敏性鼻炎适应症都处于Ⅲ期临床试验阶段， 哮喘处于Ⅱ期临床试验阶段。 ...

中国经济网北京1月22日讯 智翔金泰(688443.SH)今日股价下跌，截至收盘，该股报28.85元，跌 幅1.74%。该股目前处于破发状态。 智翔金泰于2023年6月20日在上交所科创板上市，公开发行新股9,168.0000万股，发行价格为 37.88元/股，保荐机构（主承销商）为海通证券股份有限公司（现名"国泰海通证券股份有限公司"）， 保荐代表人为王永杰、刘丹。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股 东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产 生的现金流量净额为-2.61亿元。 (责任编辑：徐自立) 智翔金泰首次公开发行股票的发行费用合计18,143.70万元（不含税），其中，保荐承销费 16,495.98万元。 智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 智翔金泰首次公 ...

Investment Rating - The report indicates a positive investment outlook for the innovative drug sector, particularly focusing on the advancements in T-cell engagers (TCE) for multiple myeloma (MM) treatment [1]. Core Insights - Johnson & Johnson's teclistamab has shown significant efficacy in the treatment of relapsed or refractory multiple myeloma (r/r MM), with a 71% reduction in disease progression or death risk and a 40% reduction in mortality risk compared to standard treatments [14][15]. - The report highlights the unmet medical needs in the MM treatment landscape, emphasizing the potential of TCE therapies targeting BCMA and GPRC5D to improve patient outcomes [9][10]. - The ongoing clinical trials and approvals for various TCE therapies, including teclistamab and talquetamab, are expected to reshape the treatment paradigm for MM, particularly in patients who have undergone multiple lines of therapy [28][34]. Summary by Sections Innovative Drug Focus - The report reviews the recent developments in innovative drugs, particularly in the context of TCE therapies for blood cancers, with a focus on their expanding applications beyond hematological malignancies [5][7]. TCE Therapy Developments - TCE therapies have gained traction in the treatment of MM, with several candidates achieving FDA approval for patients who have received multiple prior therapies. The overall response rates (ORR) for these therapies range from 60% to 74% [9][10]. - The report details the clinical trial results for teclistamab, which has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) in r/r MM patients [14][21]. Market Potential - The report estimates that the sales for teclistamab in China could reach approximately $5.49 billion by 2024, indicating a strong market potential for TCE therapies in the region [6]. - The ongoing research and development efforts in TCE therapies are expected to address the significant unmet needs in the MM treatment landscape, with a focus on improving patient outcomes and survival rates [9][10].

中国经济网北京1月19日讯 智翔金泰(688443.SH)今日股价下跌，截至收盘，该股报30.00元，跌幅 2.12%。该股目前处于破发状态。 智翔金泰于2023年6月20日在上交所科创板上市，公开发行新股9,168.0000万股，发行价格为37.88元/ 股，保荐机构（主承销商）为海通证券股份有限公司（现名"国泰海通证券股份有限公司"），保荐代表 人为王永杰、刘丹。 智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股东的 净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产生的 现金流量净额为-2.61亿元。 (责任编辑：马欣) 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14 万元。智翔金泰实际 ...

Group 1 - The independent director Hu Yuntong has submitted his resignation due to work reasons, effective immediately, and will no longer hold any position in the company [1][2] - Hu Yuntong's resignation will result in a non-compliance of the independent director ratio in the board and its committees according to legal regulations and the company's articles of association [2] - The company will expedite the election of a new independent director and ensure compliance with relevant regulations to maintain the board's structure [2] Group 2 - Hu Yuntong has made significant contributions to the company's governance and strategic development during his tenure as an independent director [2] - The board expresses sincere gratitude for Hu Yuntong's efforts and contributions to the company's growth [2]

证券代码：688443 证券简称：智翔金泰 公告编号：2026-003 一、董事离任情况 | 姓名 | 离任职务 | 离任时间 | 原定任期 | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 到期日 | | 股子公司任职 | （如适用） | 毕的公开 承诺 | | | | | | 工作原因 | | | | | | 事会薪酬 | | | | | | | | | 与考核委 | | 年 12 | | | | | | 胡耘通 | | | | | | | | | | 员会主任 | 独立董事 | 月 日 23 | | | | | | | 委员、董 | | | | | | | | | 事会审计 | | | | | | | | | 委员会委 | | | | | | | | | 第二届董 事会独立 | | | | | | | | | 董事、董 | 自公司股 | | | | | | | | | 东会选举 | | | | | | | | | 产生新任 | 2027 | | 否 | ...